About iZumi Bio
iZumi Bio, dba iPierian, is a South San Francisco-based biopharmaceutical company initially focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. Izumi was founded in 2007 and is backed by Kleiner Perkins Caufield and Byers and Highland Capital Partners. iZumi has a collaboration with The Gladstone Institute of Cardiovascular Disease and Deepak Srivastava, M.D., in the area of cardiovascular disease to identify potential targets that address unmet medical need. iZumi Bio and Pierian merged in July of 2009 to form iPierian.
Missing: iZumi Bio's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: iZumi Bio's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing iZumi Bio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
iZumi Bio is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Latest iZumi Bio News
Apr 13, 2017
XconomyNew York — Priorities change over time for drugmakers, as evidenced today by Bristol-Myers Squibb. The company announced two separate deals for experimental drugs that no longer fit its strategy—both of which were remnants of old acquisitions and a past plan to zero in on genetic diseases. In one deal, Bristol (NYSE: BMY ) has sent Biogen (NASDAQ: BIIB ), of Cambridge, MA, an experimental drug (BMS-986168) for a neurological disease called progressive supranuclear palsy (PSP). Bristol gets $300 million up front from Biogen in this deal, with another $410 million in possible future payments if the drug progresses. PSP is a devastating, rare neurodegenerative disease that causes problems walking and thinking and leads to other significant health problems, like pneumonia. There are no effective treatments. This attracted Bristol, which acquired the drug when it bought South San Francisco-based iPerian for $175 million up front in 2014 . Bristol’s R&D chief Francis Cuss noted in a statement at the time the company was zeroing in on “genetically defined diseases” where patients had limited options. iPierian’s drug is designed to stop a form of the protein Tau called “eTau” from spreading from neuron to neuron in the brain. In acquiring the PSP drug, Biogen is also now on the hook for any remaining payments due to the stockholders of iPierian, which include Kleiner Perkins Caufield & Byers, MPM Capital, GV (formerly known as Google Ventures), and SR One. Bristol’s latest annual report, filed in February , shows the company owed another $554 million in contingent payments tied to the iPierian deal. The drug just began Phase 2 testing, with results expected in 2019, according to clinicaltrials.gov . (Prior to the acquisition, meanwhile, iPierian split itself in two—the rest of the company became True North Therapeutics , which remains independent.) Another drug Bristol was developing under its genetic disease plan was a therapy acquired in a 2007 buyout of Adnexus Therapeutics. Bristol paid $415 million for Adnexus, of Waltham, MA, , a company that had been developing biologic drugs derived from the protein fibronectin. One experimental drug to come from that work was BMS-986089, a drug for Duchenne muscular dystrophy, a progressive muscle disease that puts patients in wheelchairs by their teens and often kills them at a young age from heart and lung complications. Swiss pharma giant Roche is buying BMS-986089, a drug that blocks myostatin, a protein implicated in muscle growth, for $170 million up front. BMS-986089 also recently began mid-stage testing, according to clinicaltrials.gov , and Bristol is one of several companies—among them Pfizer, Regeneron Pharmaceuticals, and Novartis—developing myostatin-blocking drugs to treat Duchenne and other diseases. Bristol could get another $205 million in downstream payments and royalties if the drug ever reaches the market. Combined, the PSP and Duchenne drugs were the only two in Bristol’s pipeline targeting genetic diseases. The drugmaker is now far more focused on cancer, where it is one of the leaders in immunotherapy, and immunology, where it has been building up a pipeline of drugs targeting fibrosis and the liver disease nonalcoholic steatohepatitis, among other disorders. Bristol’s most recent buyouts, among them Padlock Therapeutics , Flexus Biosciences , Nitto Denko, and Cormorant Pharmaceuticals , all fit within these areas. “Licensing these assets to Biogen and Roche will enable Bristol-Myers Squibb to prioritize the other promising opportunities for asset development that have advanced across our diversified portfolio,” said Mike Burgess, Bristol’s head of cardiovascular, fibrosis and immunoscience. Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at firstname.lastname@example.org Follow @benthefidler
iZumi Bio Frequently Asked Questions (FAQ)
Where is iZumi Bio's headquarters?
iZumi Bio's headquarters is located at 951 Gateway Blvd, South San Francisco.
What is iZumi Bio's latest funding round?
iZumi Bio's latest funding round is Merger.
How much did iZumi Bio raise?
iZumi Bio raised a total of $20M.
Who are the investors of iZumi Bio?
Investors of iZumi Bio include iPierian, Kleiner Perkins Caufield & Byers and Highland Capital Partners.
Who are iZumi Bio's competitors?
Competitors of iZumi Bio include ViaCyte, DiscoveryBioMed, Primorigen Biosciences, NuGEN Technologies, CytoBioscience and 12 more.
Compare iZumi Bio to Competitors
IntelCell markets a product platform engineered to modernize research techniques for cell and tissue growth. The company's first product, Cell Drive, replaces traditional cell culture equipment by providing an unprecedented level of usability and sophistication for the user. For scientists whose research depends upon live cell culture, Cell Drive aims to offer a compact, precision, cell growth system that increases experimental control, aims to improve sterility, aims to provide digitization of data and methods, and aims to reduce human error and labor costs.
Plectix BioSystems Inc. is focussed on approaches for overcoming challenges faced by biologists in the complex world of cell signaling.
DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.
AlphaGenix is a life science company located in Sioux Falls, SD that aims to develop products and technologies for basic and clinical research with a particular emphasis on stem cell biology, biomaterials and regenerative medicine. AlphaGenix sells its products non-exclusively through a world-wide network of companies. Its biomaterials, stem cell antibodies and kits are sold exclusively world-wide by Sigma-Aldrich
Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.
CellAura Technologies is a spin out company from the University of Nottingham, combining world-renowned expertise in the fields of synthetic chemistry and molecular pharmacology to produce high quality fluoresent G-protein coupled receptor ligands for use in molecular pharmacology and imaging at the single cell level.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.